These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31754710)

  • 1. Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
    Engelbrecht AE; Wiesner L; Norman J; Rabie H; Decloedt EH
    J Trop Pediatr; 2020 Aug; 66(4):385-394. PubMed ID: 31754710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
    Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
    van Luin M; Wit FW; Smit C; Rigter IM; Franssen EJ; Richter C; Kroon F; de Wolf F; Burger DM
    Ther Drug Monit; 2011 Feb; 33(1):32-9. PubMed ID: 21192311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
    Coovadia A; Abrams EJ; Strehlau R; Shiau S; Pinillos F; Martens L; Patel F; Hunt G; Tsai WY; Kuhn L
    JAMA; 2015 Nov; 314(17):1808-17. PubMed ID: 26529159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
    Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
    JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?
    von Bibra M; Rosenkranz B; Pretorius E; Rabie H; Edson C; Lenker U; Cotton M; Klinker H
    Paediatr Int Child Health; 2014 May; 34(2):138-41. PubMed ID: 24225343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy.
    Banda CG; Dzinjalamala F; Mukaka M; Mallewa J; Maiden V; Terlouw DJ; Lalloo DG; Khoo SH; Mwapasa V
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
    Reekie J; Reiss P; Ledergerber B; Sedlacek D; Parczewski M; Gatell J; Katlama C; Fätkenheuer G; Lundgren JD; Mocroft A;
    HIV Med; 2011 May; 12(5):259-68. PubMed ID: 20812948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir.
    Caswell RJ; Phillips D; Chaponda M; Khoo SH; Taylor GP; Ghanem M; Poulton M; Welch J; Gibbons S; Jackson V; Lambert JS
    Int J STD AIDS; 2011 Jan; 22(1):11-4. PubMed ID: 21364060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
    Nachega JB; Hislop M; Dowdy DW; Gallant JE; Chaisson RE; Regensberg L; Maartens G
    AIDS; 2008 Oct; 22(16):2117-25. PubMed ID: 18832875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
    Gunda DW; Kasang C; Kidenya BR; Kabangila R; Mshana SE; Kidola J; Kalluvya SE; Kongola GW; Klinker H
    PLoS One; 2013; 8(9):e75118. PubMed ID: 24058655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?
    Aarnoutse RE; Schapiro JM; Boucher CA; Hekster YA; Burger DM
    Drugs; 2003; 63(8):741-53. PubMed ID: 12662123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How well does self-reported adherence fare compared to therapeutic drug monitoring in HAART?
    Bulgiba A; Mohammed UY; Chik Z; Lee C; Peramalah D
    Prev Med; 2013; 57 Suppl():S34-6. PubMed ID: 23313585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
    Cattaneo D; Baldelli S; Castoldi S; Charbe N; Cozzi V; Fucile S; Clementi E
    AIDS; 2014 Oct; 28(16):2477-80. PubMed ID: 25392858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efavirenz--comprehensive status of studies].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():79-81. PubMed ID: 16385886
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    Winston A; Pozniak A; Smith N; Fletcher C; Mandalia S; Parmar D; Gibbons S; Back D; Gazzard B; Nelson M
    AIDS; 2004 Feb; 18(3):572-4. PubMed ID: 15090815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
    Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
    BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.